Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

摘要: Background Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, product of Philadelphia chromosome. Imatinib mesylate, formerly STI571, a selective inhibitor this kinase. Methods A total 532 patients with late–chronic-phase CML in whom previous therapy interferon alfa had failed were treated 400 mg oral imatinib daily. Patients evaluated for cytogenetic and hematologic responses. Time to progression, survival, toxic effects also evaluated. Results induced major responses 60 percent 454 confirmed chronic-phase complete 95 percent. After median follow-up 18 months, not progressed accelerated or blast phases an estimated 89 patients, alive. Grade 3 4 nonhematologic infrequent, manageable. Only 2 discontinued treatment be...